Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses prognostic markers and high-risk features in mantle cell lymphoma (MCL), including p53 mutation, high-Ki 67, and blastoid morphology. Dr Eyre also comments on the importance of planning treatment with CAR-T therapy in advance for patients with high-risk disease, and the promising responses obtained with the use of CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
